ArticleFrontiers in endocrinology2025
Microwave ablation vs. surgery for thyroid microcarcinoma near the capsule: a propensity-matched study on safety and efficacy.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ultrasound-guided microwave ablation (MWA) has been widely used as an efficient and safe minimally invasive treatment for papillary thyroid microcarcinomas (PTMCs). However, controversy persists regarding its application for PTMCs adjacent to the thyroid capsule. This study aimed to compare the feasibility, efficacy, and safety of MWA versus surgery for US-detected PTMCs closely abutting the capsule. Materials and methods: This retrospective study included 364 PTMC patients from January 2019 to September 2024, comprising 69 in the MWA group and 295 in the surgical group. Propensity score matching (PSM) was used to balance baseline characteristics between groups. Based on maximum nodule diameter, patients were stratified into ≤5 mm and >5mm subgroups. Primary outcomes included technical success, postoperative complications, and tumor progression; secondary outcomes encompassed changes in tumor size/volume and treatment-related variables (hospital stay, operative duration, estimated blood loss, and costs). Results: After PSM, 94 patients underwent surgery (mean age 43.89±11.50 years) and 67 received MWA (mean age 45.27±10.66 years). Follow-up durations were 31.00±1.66 (MWA) and 31.57±16.00 months (surgery). Both groups achieved 100% technical success, with no significant difference in complication rates (3.0% vs. 3.3%, Conclusion: MWA demonstrates comparable short-term outcomes to surgery for PTMCs adjacent to the capsule, offering a safe and effective therapeutic alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.